Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer

Abstract EN

Purpose.

Circulating autoantibodies have been extensively investigated as possible markers for early diagnosis of cancer.

The present study was carried out to investigate whether anti-LGALS3BP IgG autoantibodies could be classified as a biomarker for malignant tumors.

Methods.

An in-house developed enzyme-linked immunosorbent assay was used to detect autoantibodies to LGALS3BP in sera from 71 patients with various types of cancers and 54 healthy subjects matched by age and gender.

Results.

Patients with cancer have significant higher circulating levels of anti-LGALS3BP antibodies as compared to control subjects (P<0.001).

The test has a sensitivity of 33% and a specificity of 98%.

Conclusions.

Anti-LGALS3BP IgG autoantibodies are a promising biomarker for malignant tumors and could play a role in the development of a multimarker assay for the early detection of cancer.